Meeder Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Meeder Asset Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,346	Closed	-$5K	–	2515
2020 Q1	$5K	Buy	2,346 +1,437	+158%	+$6.18K	﹤0.01%	1815
2019 Q4	$6K	Sell	909 -184	-17%	-$1.52K	﹤0.01%	1744
2019 Q3	$11K	Buy	1,093 +712	+187%	+$8K	﹤0.01%	1511
2019 Q2	$4K	Hold	381	–	–	﹤0.01%	1749
2019 Q1	$4K	Buy	+381	New	+$4.88K	﹤0.01%	1458

Other funds holding XERS

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Meeder Asset Management's XERS Position: Q2 2020 in Review

Meeder Asset Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2020, closing a stake of 2,346 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in XERS in Q1 2019 and held it in 5 quarters. The position peaked at $11K in Q3 2019. 86 funds tracked by Wall St. Rank hold XERS as of Q2 2020.

Meeder Asset Management reported no remaining Xeris Biopharma Holdings position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 2,346 Xeris Biopharma Holdings shares in Q2 2020, an estimated $5K.
Meeder Asset Management first reported a position in Xeris Biopharma Holdings in Q1 2019 and held it in 5 quarters.
Meeder Asset Management's Xeris Biopharma Holdings position peaked at $11K in Q3 2019.
86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.